These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 28104306)

  • 41. Clinical Outcomes in Patients Treated With Biodegradable-Polymer Biolimus-Eluting Stents and 6 Months of Dual-Antiplatelet Therapy: The French eBiomatrix 6-Month DAPT Registry.
    Lipiecki J; Rampat R; Piot C; Benamer H; Brunelle F; Lefèvre T; El Mahmoud R; Varenne O; Gommeaux A; Malquarti V; Angoulvant D; Cruchon C; Oldroyd K; Spaulding C
    J Invasive Cardiol; 2022 May; 34(5):E363-E368. PubMed ID: 35451995
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Outcomes of the amphilimus-eluting polymer-free stent for chronic total occlusion treatment: a multicentre experience.
    Maeremans J; Cottens D; Azzalini L; Pereira B; Godino C; Carlino M; Colombo A; Frambach P; Bellini B; Candilio L; Briguori C; Pierri A; Lamers S; Roux L; Duponselle J; Vrolix M; Dens J
    J Cardiovasc Med (Hagerstown); 2018 Oct; 19(10):564-570. PubMed ID: 30124545
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A randomized, double-blind, multicenter comparison study of triple antiplatelet therapy with dual antiplatelet therapy to reduce restenosis after drug-eluting stent implantation in long coronary lesions: results from the DECLARE-LONG II (Drug-Eluting Stenting Followed by Cilostazol Treatment Reduces Late Restenosis in Patients with Long Coronary Lesions) trial.
    Lee SW; Park SW; Kim YH; Yun SC; Park DW; Lee CW; Kang SJ; Park SJ; Lee JH; Choi SW; Seong IW; Lee NH; Cho YH; Shin WY; Lee SJ; Lee SW; Hyon MS; Bang DW; Choi YJ; Kim HS; Lee BK; Lee K; Park HK; Park CB; Lee SG; Kim MK; Park KH; Park WJ;
    J Am Coll Cardiol; 2011 Mar; 57(11):1264-70. PubMed ID: 21392640
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Multicenter randomized trial of 3-month cilostazol use in addition to dual antiplatelet therapy after biolimus-eluting stent implantation for long or multivessel coronary artery disease.
    Youn YJ; Lee JW; Ahn SG; Lee SH; Choi H; Yu CW; Hong YJ; Kwon HM; Hong MK; Jang Y; Yoon J
    Am Heart J; 2014 Feb; 167(2):241-248.e1. PubMed ID: 24439986
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Safety of 6-month duration of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndromes: Rationale and design of the Smart Angioplasty Research Team-safety of 6-month duration of Dual Antiplatelet Therapy after percutaneous coronary intervention in patients with acute coronary syndromes (SMART-DATE) prospective multicenter randomized trial.
    Lee JM; Cho DK; Hahn JY; Song YB; Park TK; Oh JH; Lee JB; Doh JH; Kim SH; Yang JH; Choi JH; Choi SH; Lee SH; Gwon HC
    Am Heart J; 2016 Dec; 182():1-8. PubMed ID: 27914488
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Duration of clopidogrel-based dual antiplatelet therapy and clinical outcomes after endeavor sprint zotarolimus-eluting stent implantation in patients presenting with acute coronary syndrome.
    Song PS; Hahn JY; Kim DI; Song YB; Choi SH; Choi JH; Ryu DR; Hur SH; Jeong JO; Park HS; Kim HS; Gwon HC
    Eur J Intern Med; 2015 Sep; 26(7):521-7. PubMed ID: 26153337
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Impact of clinical presentation on ischaemic and bleeding outcomes in patients receiving 6- or 24-month duration of dual-antiplatelet therapy after stent implantation: a pre-specified analysis from the PRODIGY (Prolonging Dual-Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia) trial.
    Costa F; Vranckx P; Leonardi S; Moscarella E; Ando G; Calabro P; Oreto G; Zijlstra F; Valgimigli M
    Eur Heart J; 2015 May; 36(20):1242-51. PubMed ID: 25718355
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Safety and efficacy of biodegradable polymer-coated sirolimus-eluting stents in "real-world" practice: 18-month clinical and 9-month angiographic outcomes.
    Han Y; Jing Q; Xu B; Yang L; Liu H; Shang X; Jiang T; Li Z; Zhang H; Li H; Qiu J; Liu Y; Li Y; Chen X; Gao R;
    JACC Cardiovasc Interv; 2009 Apr; 2(4):303-9. PubMed ID: 19463441
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Patterns and associations between DAPT cessation and 2-year clinical outcomes in left main/proximal LAD versus other PCI: Results from the Patterns of Non-Adherence to Dual Antiplatelet Therapy in Stented Patients (PARIS) registry.
    Chandrasekhar J; Baber U; Sartori S; Aquino M; Tomey M; Kruckoff M; Moliterno D; Henry TD; Weisz G; Gibson CM; Iakovou I; Kini A; Faggioni M; Vogel B; Farhan S; Colombo A; Steg PG; Witzenbichler B; Chieffo A; Cohen D; Stuckey T; Ariti C; Pocock S; Dangas G; Mehran R
    Int J Cardiol; 2017 Sep; 243():132-139. PubMed ID: 28554669
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Rationale and design of a randomized, double-blind, placebo-controlled trial of 6 versus 12 months clopidogrel therapy after implantation of a drug-eluting stent: The Intracoronary Stenting and Antithrombotic Regimen: Safety And EFficacy of 6 Months Dual Antiplatelet Therapy After Drug-Eluting Stenting (ISAR-SAFE) study.
    Byrne RA; Schulz S; Mehilli J; Iijima R; Massberg S; Neumann FJ; ten Berg JM; Schömig A; Kastrati A;
    Am Heart J; 2009 Apr; 157(4):620-4.e2. PubMed ID: 19332187
    [TBL] [Abstract][Full Text] [Related]  

  • 51. One-Month Dual Antiplatelet Therapy in Patients With Chronic and Acute Coronary Syndromes Treated With Bioresorbable Polymer Everolimus-Eluting Stents.
    Musto C; Paolucci L; Pivato CA; Testa L; Pacchioni A; Briguori C; Esposito G; Piccolo R; Lucisano L; De Luca L; Conrotto F; Sanz-Sanchez J; Cesario V; De Felice F; Latini AC; Regazzoli D; Sardella G; Indolfi C; Reimers B; Condorelli G; Stefanini G
    Am J Cardiol; 2023 Nov; 207():170-178. PubMed ID: 37741107
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The optimal duration of dual antiplatelet therapy in patients receiving percutaneous coronary intervention with drug-eluting stents.
    Sheyin O; Perez X; Pierre-Louis B; Kurian D
    Cardiol J; 2016; 23(3):307-16. PubMed ID: 26711462
    [TBL] [Abstract][Full Text] [Related]  

  • 53. First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries).
    Ormiston J; Webster M; Stewart J; Vrolix M; Whitbourn R; Donohoe D; Knape C; Lansky A; Attizzani GF; Fitzgerald P; Kandzari DE; Wijns W
    JACC Cardiovasc Interv; 2013 Oct; 6(10):1026-34. PubMed ID: 24055443
    [TBL] [Abstract][Full Text] [Related]  

  • 54. One-year outcome of a prospective trial stopping dual antiplatelet therapy at 3 months after everolimus-eluting cobalt-chromium stent implantation: ShortT and OPtimal duration of Dual AntiPlatelet Therapy after everolimus-eluting cobalt-chromium stent (STOPDAPT) trial.
    Natsuaki M; Morimoto T; Yamamoto E; Shiomi H; Furukawa Y; Abe M; Nakao K; Ishikawa T; Kawai K; Yunoki K; Shimizu S; Akao M; Miki S; Yamamoto M; Okada H; Hoshino K; Kadota K; Morino Y; Igarashi K; Tanabe K; Kozuma K; Kimura T
    Cardiovasc Interv Ther; 2016 Jul; 31(3):196-209. PubMed ID: 26518420
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Is Bare-Metal Stent Implantation Still Justifiable in High Bleeding Risk Patients Undergoing Percutaneous Coronary Intervention?: A Pre-Specified Analysis From the ZEUS Trial.
    Ariotti S; Adamo M; Costa F; Patialiakas A; Briguori C; Thury A; Colangelo S; Campo G; Tebaldi M; Ungi I; Tondi S; Roffi M; Menozzi A; de Cesare N; Garbo R; Meliga E; Testa L; Gabriel HM; Ferlini M; Vranckx P; Valgimigli M;
    JACC Cardiovasc Interv; 2016 Mar; 9(5):426-36. PubMed ID: 26965932
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Short versus prolonged dual antiplatelet therapy duration after bare-metal stent implantation: 2-month landmark analysis from the CREDO-Kyoto registry cohort-2.
    Natsuaki M; Morimoto T; Furukawa Y; Nakagawa Y; Kadota K; Ando K; Shiomi H; Toyota T; Watanabe H; Ono K; Shizuta S; Tamura T; Inoko M; Inada T; Shirotani M; Matsuda M; Aoyama T; Onodera T; Suwa S; Takeda T; Inoue K; Kimura T;
    Cardiovasc Interv Ther; 2018 Jan; 33(1):23-34. PubMed ID: 27646646
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Randomized comparison of Zotarolimus-Eluting Endeavor Sprint versus bare-metal stent implantation in uncertain drug-eluting stent candidates: rationale, design, and characterization of the patient population for the Zotarolimus-eluting Endeavor Sprint stent in uncertain DES candidates study.
    Valgimigli M; Patialiakas A; Thury A; Colangelo S; Campo G; Tebaldi M; Ungi I; Tondi S; Roffi M; Menozzi A; de Cesare N; Garbo R; Meliga E; Testa L; Gabriel HM; Airoldi F; Ferlini M; Liistro F; Dellavalle A; Vranckx P; Briguori C
    Am Heart J; 2013 Nov; 166(5):831-8. PubMed ID: 24176438
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Initial Experience of Bioabsorbable Polymer Everolimus-Eluting Synergy Stents in High-Risk Patients Undergoing Complex Percutaneous Coronary Intervention With Early Discontinuation of Dual-Antiplatelet Therapy.
    Noad RL; Hanratty CG; Walsh SJ
    J Invasive Cardiol; 2017 Feb; 29(2):36-41. PubMed ID: 27974669
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy of Xience/promus versus Cypher in rEducing Late Loss after stENTing (EXCELLENT) trial: study design and rationale of a Korean multicenter prospective randomized trial.
    Park KW; Yoon JH; Kim JS; Hahn JY; Cho YS; Chae IH; Gwon HC; Ahn T; Oh BH; Park JE; Shim WH; Shin EK; Jang YS; Kim HS
    Am Heart J; 2009 May; 157(5):811-817.e1. PubMed ID: 19376305
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A multicenter randomized trial comparing amphilimus- with paclitaxel-eluting stents in de novo native coronary artery lesions.
    Carrié D; Berland J; Verheye S; Hauptmann KE; Vrolix M; Violini R; Dibie A; Berti S; Maupas E; Antoniucci D; Schofer J
    J Am Coll Cardiol; 2012 Apr; 59(15):1371-6. PubMed ID: 22284328
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.